Guideline concordant primary treatment and race/ethnicity by breast cancer subtypes
Non-Hispanic white | African American | Hispanic white | Asian/Pacific Islander | American Indian/Alaska Native | |||||
---|---|---|---|---|---|---|---|---|---|
n = 26,980 | n = 3,380 | n = 3,428 | n = 3,066 | n = 199 | |||||
n (%) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | |
All subtypesa | |||||||||
Concordant | 23,538 (87.2) | 2,774 (82.1) | Ref | 2,882 (84.1) | Ref | 2,691 (87.8) | Ref | 168 (84.4) | Ref |
Nonconcordant | 3,442 (12.8) | 606 (17.9) | 1.4 (1.3–1.6) | 546 (15.9) | 1.3 (1.2–1.4) | 375 (12.2) | 1.0 (0.9–1.1) | 31 (15.6) | 1.3 (0.9–1.9) |
HR+/HER2−b | |||||||||
Concordant | 18,994 (88.1) | 1,926 (84.4) | Ref | 2,220 (85.4) | Ref | 2,104 (88.5) | Ref | 140 (84.3) | Ref |
Nonconcordant | 2,577 (11.9) | 357 (15.6) | 1.3 (1.2–1.5) | 380 (14.6) | 1.3 (1.1–1.4) | 275 (11.5) | 1.0 (0.8–1.1) | 26 (15.7) | 1.3 (0.9–2.1) |
Triple negativeb | |||||||||
Concordant | 1,862 (83.2) | 447 (75.1) | Ref | 282 (80.6) | Ref | 174 (86.6) | Ref | 7 (77.8) | Ref |
Nonconcordant | 376 (16.8) | 148 (24.9) | 1.6 (1.3–2.0) | 68 (19.4) | 1.2 (0.9–1.6) | 27 (13.4) | 0.8 (0.5–1.2) | 2 (22.2) | 1.5 (0.3–7.1) |
HR+/HER2+b | |||||||||
Concordant | 1,951 (84.3) | 277 (79.6) | Ref | 269 (79.1) | Ref | 268 (83.0) | Ref | 14 (82.4) | Ref |
Nonconcordant | 363 (15.7) | 71 (20.4) | 1.4 (1.0–1.8) | 71 (20.9) | 1.4 (1.1–1.9) | 55 (17.0) | 1.1 (0.8–1.5) | 3 (17.6) | 1.2 (0.3–4.1) |
HR−/HER2+b | |||||||||
Concordant | 731 (85.3) | 124 (80.5) | Ref | 111 (80.4) | Ref | 145 (89.0) | Ref | 7 (100.0) | NA |
Nonconcordant | 126 (14.7) | 30 (19.5) | 1.4 (0.9–2.2) | 27 (19.6) | 1.5 (0.9–2.4) | 18 (11.0) | 0.7 (0.4–1.2) | 0 (0.0) |